Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Samsung Medical Center

Status and phase: Unknown; Phase 2

Conditions: Nasopharyngeal Cancer

Treatments: Drug: Docetaxel, Cisplatin

Study type: Interventional

Funder types: Other

Identifiers

NCT01312311

2006-07-005

Details and patient eligibility

About

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Enrollment: 51 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• histologically confirmed nasopharyngeal cancer
• chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment)
• ECOG 0-1
• at least one measurable lesion

Exclusion criteria

• other cancer
• pregnat
• docetaxel hypersentitivity history
• severe heart or pulmonary disease

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

51 participants in 1 patient group

weekly docetaxel and cisplatin

Experimental group

Description:

Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1 every 3 weeks maxinum 6 cycles

Treatment:

Drug: Docetaxel, Cisplatin